Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes 10.1056/NEJMoa021778

Aarhus University, Aarhus, Central Jutland, Denmark
New England Journal of Medicine (Impact Factor: 55.87). 02/2003; 348(5):383-93. DOI: 10.1056/NEJMoa021778
Source: PubMed


Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.
The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin.
The mean age of the patients was 55.1 years, and the mean follow-up was 7.8 years. The decline in glycosylated hemoglobin values, systolic and diastolic blood pressure, serum cholesterol and triglyceride levels measured after an overnight fast, and urinary albumin excretion rate were all significantly greater in the intensive-therapy group than in the conventional-therapy group. Patients receiving intensive therapy also had a significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95 percent confidence interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79).
A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.

Full-text preview

Available from:
  • Source
    • "Left unmanaged, this can lead to heart disease (Gaede et al., 2003; Grover et al., 2014), stroke (Patel et al., 2008), kidney failure, and death (Inzucchi et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study examined the association between attributing self-reported discrimination to weight and diabetes outcomes (glycemic control, diabetes-related distress, and diabetes self-care). A community dwelling sample of 185 adults (mean age 55.4; 80 % White/Caucasian 65 % female) with poorly controlled type 2 diabetes (HbA1c level ≥7.5 %) provided demographic and several self-report measures (including diabetes-related distress, diabetes self-care activities, discrimination, and attributions of discrimination), and had height, weight, and glycated hemoglobin (HbA1c) assessed by trained research staff as part of a larger research study. Individuals who attributed self-reported discrimination to weight had significantly higher HbA1c levels, higher levels of diabetes-related distress, and worse diabetes-related self-care behaviors (general diet, exercise, and glucose testing). These relationships persisted even when controlling for BMI, overall discrimination, depressive symptoms, and demographic characteristics. Results indicate that the perception of weight stigma among individuals with type 2 diabetes is strongly associated with a range of poor diabetes outcomes. Efforts to reduce exposure to and/or teach adaptive coping for weight stigma may benefit patients with type 2 diabetes.
    Full-text · Article · Jul 2015 · Journal of Behavioral Medicine
  • Source
    • "Statins inhibit 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase, thereby decreasing the conversion of HMG-CoA to mevalonate, the rate-limiting step of cholesterol biosynthesis [12]. Improved treatment of hyperglycemia, and other risk factors associated with DM2 and metabolic syndrome is thus required, because this would make it possible to markedly lower the risk of both micro-and macrovascular complications [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of type 2 diabetes mellitus is increasing rapidly, and its treatment with pioglitazone is likely to induce rhabdomyolysis. We aimed to determine the effect of cotreatment with pioglitazone and red mold dioscorea (RMD) produced by Monascus purpureus NTU 568 on pancreas function in streptozotocin (STZ)-induced diabetic rats. In diabetic rats fed RMD, RMD with pioglitazone, and pioglitazone alone, insulin concentrations increased significantly by 18.6–40.4%, 64.0–100.0%, and 52.8%, respectively, compared with that in the diabetic group (p < 0.05). Oral glucose tolerance was impaired in the STZ-induced diabetic group within 4 weeks, however, oral glucose tolerance in rats treated with RMD or RMD with pioglitazone improved after 4 weeks, 6 weeks, and 8 weeks. Findings from this study might lend support to the use of RMD as a novel functional food for the prevention of diabetes.
    Full-text · Article · Jul 2015 · Journal of Food and Drug Analysis
  • Source
    • "Hypertension increases the risk of DM related complications such as stroke [34]. Randomized clinical trials have previously demonstrated improved outcomes in diabetic patients with a better blood pressure (BP) control, especially at systolic BP treatment goal of 130 to 135 mm Hg [35] [36]. However; in RE-LY, 1014 (24%) and 1918 (45%) patients with DM had a systolic blood pressure of more than 140 mm Hg and 130 mm Hg, respectively suggesting that improved diagnosis and management of hypertension could be an important, additional means of stroke prevention among patients with AF and DM [37] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus (DM) is frequent among patients with atrial fibrillation (AF). The RE-LY trial permits evaluation of patient characteristics, outcomes and the effectiveness of dabigatran etexilate among diabetic individuals. Patient characteristics and outcomes were compared between diabetic and non-diabetic patients and the relative efficacy of each dose of dabigatran (150mg bid and 110mg bid) versus warfarin was evaluated. Of 18,113 patients in RE-LY, 4221 patients (23.3%) had DM. Patients with DM were younger (70.9 vs. 71.7years), more likely to have hypertension (86.6% vs. 76.5%), coronary artery disease (37.4% vs. 24.9%) and peripheral vascular disease (5.6% vs. 3.2%); (all p<0.01). Time in therapeutic range for warfarin-treated patients was 65% for diabetic versus 68% for non-diabetic patients (p<0.001). Regardless of assigned treatment, stroke or systemic embolism was more common among patients with DM (1.9% per year vs. 1.3% per year, p<0.001). DM was also associated with an increased risk of death (5.1% per year vs. 3.5% per year, p<0.001) and major bleeding (4.2% per year vs. 3.0% per year, p<0.001). The absolute reduction in stroke or systemic embolism with dabigatran compared to warfarin was greater among patients with DM than those without DM (dabigatran 110mg: 0.59% per year vs. 0.05% per year; dabigatran 150mg: 0.89% per year vs. 0.51% per year). Compared to non-DM patients, AF patients with DM derive a greater absolute risk reduction in embolic events when treated with dabigatran. Identifier: NCT00262600. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Full-text · Article · May 2015 · International Journal of Cardiology
Show more